Form 4: Fennec Pharmaceuticals CEO Rosty Raykov Reports Share Transactions
SEC Form 4
Fennec Pharmaceuticals CEO Rosty Raykov reports the acquisition and disposal of common shares, including shares sold under a 10b5-1 plan.
Summary
- On July 1, 2024, Rosty Raykov, CEO of Fennec Pharmaceuticals, acquired 2,431 common shares.
- These shares were acquired at a price of $0, increasing his holdings to 189,902 shares.
- On July 2, 2024, Raykov disposed of 2,431 common shares at a price of $6.13 per share.
- This disposal decreased his holdings to 187,471 shares.
- The sale was executed pursuant to a 10b5-1 plan dated December 14, 2023.
- The initial acquisition of 2,431 shares on July 1, 2024, represents the release of restriction from shares awarded on March 31, 2023.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives to utilize 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the small volume of shares traded.
Key Dates
| Date | Description |
|---|---|
| 2023-03-31 | Date of original share award. |
| 2023-12-14 | Date of 10b5-1 plan adoption. |
| 2024-07-01 | Acquisition of 2,431 common shares. |
| 2024-07-02 | Sale of 2,431 common shares. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.